Yan Leyfman, MD

#MultipleMyeloma #CAR_T #Talquetamab #RRMM #Oncology #Hematology #CellTherapy #RealWorldEvidence #MyelomaResearch #Immunotherapy #GPRC5D #BCMA

Evidence of sustained CAR-T expansion around day 14

💡 Conclusion:

Talquetamab is emerging as a promising bridging option to BCMA CAR-T, particularly for high-risk, trial-ineligible patients who are otherwise vulnerable to disease progression during CAR-T manufacturing.

Toxicity profile: no grade ≥3 CRS, 2% grade 3 ICANS; common but manageable talquetamab-related side effects (oral 70%, skin 38%, nails 17%)

🧠 CAR-T Outcomes Post-Bridging:

88% overall response rate (54% complete response)

Minimal grade ≥3 toxicity post-infusion

🧬 Bridging Outcomes:

71% response rate to talquetamab

119/134 patients proceeded to CAR-T (98 cilta-cel, 21 ide-cel)

Median talquetamab duration: 23 days

Most received 0.8 mg/kg biweekly

👥 Patient Cohort (n=134):

Median age: 65

Median prior therapies: 5

44% with high-risk cytogenetics

41% with extramedullary disease

85% ineligible for CARTITUDE-1/KarMMa trials

📊 Study Overview:

A multi-institutional retrospective analysis (20 centers: 18 US, 2 Germany) evaluated talquetamab, a GPRC5D-targeting bispecific antibody, as bridging therapy prior to CAR-T infusion in relapsed/refractory multiple myeloma (RRMM).

It allowed transition to BCMA CAR-T (cilta-cel or ide-cel) in heavily pretreated, high-risk patients, including many who would not have qualified for clinical trials.

Sequential Targeting in Multiple Myeloma: Talquetamab, a GPRC5D bispecific antibody, as a Bridge to BCMA CAR-T cell therapy Key Points. Talquetamab bridging is feasible, safe and effective allowing rapid disease control with minimal grade toxicity.Talquetamab enabled transition

🧪 Real-world study supports talquetamab as a viable bridging strategy to BCMA CAR-T in RRMM 🔄

📌 Key Takeaways:

Talquetamab bridging is feasible, safe, and effective, enabling rapid disease control with low-grade toxicities.

Thank you

Thank you for your support

#MitochondrialDonation #mtDNA #ReproductiveMedicine #GeneticCounseling #WomensHealth #PrecisionMedicine #MitochondrialDisease #FertilityInnovation

Mitochondrial Donation in a Reproductive Care Pathway for mtDNA Disease | NEJM Pathogenic variants in mitochondrial DNA (mtDNA) are a common cause of severe, often fatal, inherited metabolic disease. A reproductive care pathway was implemented to provide women carrying pathog...

This marks a major step forward in preventing transmission of mitochondrial disease and offering families new hope through advanced reproductive technologies.

manuscript: www.nejm.org/doi/full/10....

🔹 All infants had no or low mtDNA heteroplasmy

🔹 Minor postnatal issues were manageable and resolved

🔹 Normal developmental progress observed in all children

Mitochondrial Donation in a Reproductive Care Pathway for mtDNA Disease | NEJM Pathogenic variants in mitochondrial DNA (mtDNA) are a common cause of severe, often fatal, inherited metabolic disease. A reproductive care pathway was implemented to provide women carrying pathog...

🧬✨ Hope Through Mitochondrial Donation

A UK reproductive program offering pronuclear transfer (a form of mitochondrial donation) to women with pathogenic mtDNA variants has resulted in 8 healthy live births.

Thank you for your support

Thank you for your support

Thank you for your support

👉 Register now: globalmeet.webcasts.com/starthere.js...

#FollicularLymphoma #LymphomaCare #Oncology #WomenInMedicine #HemeOnc #VoicesInLymphoma #MedTwitter #GlobalOncology @onclive.bsky.social @womeninlymphoma.bsky.social

From evidence-based first-line strategies to evolving care pathways, this session offers deep clinical insights and global perspectives.

📌 Whether you're in clinic, research, or just passionate about hematologic oncology, this is a session you don’t want to miss.

Join us for an empowering discussion led by two global experts shaping the future of follicular lymphoma care:

👩‍⚕️ Dr. Clémentine Sarkozy

Hematologist, Institut Curie, France

👩‍⚕️ Dr. Carla Casulo

University of Rochester, Wilmot Cancer Institute

🎥 MedNews Week x OncLive x Women in Lymphoma Present:

🌟 Voices in Lymphoma: Women Shaping Care 🌟

💡 Follicular Lymphoma: General Concept and First Line Strategies

🗓️ Tuesday, July 15

⏰ 6:30 PM EST

Yan Leyfman: AI's Role in Guiding Immunotherapy Decisions in Nasopharyngeal Carcinoma - OncoDaily Yan Leyfman: AI's Role in Guiding Immunotherapy Decisions in Nasopharyngeal Carcinoma / C. Huang, C. Xie, cancer, Cancer research, F. Xie, F. Zhong, J. Chen,

AI’s Role in Guiding Immunotherapy Decisions in Nasopharyngeal Carcinoma - Yan Leyfman
@yleyfman.bsky.social

oncodaily.com/insight/yan-...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #AI #NPC #NasopharyngealCarcinoma

A reference model of circulating hematopoietic stem cells across the lifespan with applications to diagnostics - Nature Medicine A large single-cell transcriptomic-based reference model for hematopoietic stem and progenitor cells from 148 age- and sex-diverse individuals identifies physiological and disease-specific changes acr...

manuscript: www.nature.com/articles/s41...

#Hematology #Oncology #PrecisionMedicine #BloodCancer

The team’s work also sheds light on how aging blood stem cells vary by sex, helping explain the higher prevalence of blood cancers in men.

This diagnostic approach is now being tested in large-scale clinical trials worldwide, with potential applications beyond MDS and leukemia.

A simple blood test analyzing rare circulating stem cells can:

✅ Detect early signs of myelodysplastic syndrome (MDS)

✅ Assess leukemia risk—non-invasively

✅ Potentially replace painful bone marrow biopsies

A reference model of circulating hematopoietic stem cells across the lifespan with applications to diagnostics - Nature Medicine A large single-cell transcriptomic-based reference model for hematopoietic stem and progenitor cells from 148 age- and sex-diverse individuals identifies physiological and disease-specific changes acr...

A breakthrough for blood cancer detection?

In a Nature Medicine study—published just days after their labs were damaged in an Iranian missile attack—Shlush, Tanay, Furer, Milman & Rappoport reveal a potential game-changer:

Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes | NEJM Orforglipron is a small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist in clinical development for type 2 diabetes and weight management. Additional data on the efficacy and ...

This could mark a major step forward in oral GLP-1 therapies for type 2 diabetes.

manuscript: www.nejm.org/doi/full/10....

#Diabetes #GLP1 #Orforglipron #WeightManagement #Endocrinology #ClinicalTrials

✅ Significant reduction in A1c at all doses by week 40

✅ Up to 7.6% weight loss with the highest dose

✅ Well-tolerated, mostly mild-to-moderate GI side effects

✅ No severe hypoglycemia reported

Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes | NEJM Orforglipron is a small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist in clinical development for type 2 diabetes and weight management. Additional data on the efficacy and ...

🚨 Latest in Type 2 Diabetes & Weight Management 🚨

New data from the phase 3 ACHIEVE-1 trial shows promising results for Orforglipron, a once-daily, oral, nonpeptide GLP-1 receptor agonist.

#FDAApproval #Yeztugo #HIVPrevention #MedicalBreakthrough #PrEP #EndHIV #PublicHealth #GlobalImpact #InnovationInMedicine